Experimental study of adenovirus vector mediated-hVEGF165 gene on prevention of restenosis after angioplasty.
This study evaluated the effects of adenovirus vector mediated human vascular endothelial growth factor-165 (hVEGF165) gene on prevention of restenosis after angioplasty. Rabbit models of bilateral carotid artery injury were established by balloon denudation. The recombinant adenoviruses containing hVEGF165 cDNA was directly injected into left side of the injured carotid arteries. On day 3 and week 3 after transfection the expression of VEGF was observed by RT-PCR and immunohistochemistry. The thrombokinesis, reendothelialization (rET) and intimal hyperplasia in carotid arteries were evaluated by computerized image analysis system 3 weeks after gene transfer. The changes in the VEGF gene-treated side were compared with the control side. Our results showed that 3 days and 3 weeks after hVEGF165 gene transfer the VEGF mRNA and antigen expression were detected in vivo. 3 weeks after the transfer, the carotid artery rET was markedly better in the VEGF gene-treated group compared with the control. The thrombokinesis, intima area/media area (I/M), maximal intimal and medial thicknesses (ITmax and MTmax) demonstrated a statistically significant decrease in arteries treated with VEGF gene as compared with the control group. It is concluded that VEGF gene transfer could be achieved by intra-arterial injection of recombinant adenoviruses. It might accelerate the restoration of endothelial integrity, inhibit thrombokinesis and attenuate intimal hyperplasia in the injured arteries after VEGF gene transfer. This procedure could be useful in preventing restenosis after angioplasty.
Liu
Qigong
Q
Department of Cardiology, Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan 430030, China.
Lu
Zaiying
Z
Yue
Yuankun
Y
Lin
Li
L
Zhang
Weidong
W
Yan
Jin
J
D000256:Adenoviridae / Q000235:genetics / Q000378:metabolism; D000800:Angioplasty, Balloon / Q000009:adverse effects*; D000818:Animals; D020212:Carotid Artery Injuries / Q000473:pathology; D016893:Carotid Stenosis / Q000503:physiopathology / Q000517:prevention & control*; D002455:Cell Division / Q000187:drug effects; D004730:Endothelium, Vascular / Q000293:injuries* / Q000473:pathology; D015316:Genetic Therapy; D006965:Hyperplasia / Q000517:prevention & control; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011817:Rabbits; D011995:Recombination, Genetic; D014162:Transfection / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000235:genetics
D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A